DiaGenic

NEW YORK (GenomeWeb News) – Norwegian biomarker diagnostics firm DiaGenic today announced the initiation of a cost reduction program, which includes the elimination of an undisclosed number of jobs.

Norwegian molecular diagnostic developer DiaGenic said this week that it has adopted Life Technologies' recently launched QuantStudio Dx platform to further enable development of its pipeline of multi-biomarker blood-based molecular assays for Alzheimer's disease.

DiaGenic has named Paul de Potocki as president and CEO, effective in September.

NEW YORK (GenomeWeb News) – DiaGenic today said that it has received a NOK 7.8 million ($1.3 million) grant from the Norwegian Research Council for an Alzheimer's disease diagnostics program.

DiaGenic said this week that CEO Erik Christensen has resigned.
Christensen will "continue to provide consultative support to the company on partner interactions, licensing and other business activities," DiaGenic said in a statement.

The story has been updated to clarify the nature of the test in the headline.
By a GenomeWeb staff reporter

After the split, the Norwegian firm had about 27 million shares of common stock outstanding.

The firm terminated its market-making contract with the investment firm, as trading of its stock has been "very high."

The firms will use DiaGenic's gene expression technology in a study to identify biomarkers related to patients who progress from mild cognitive impairment to Alzheimer's.

Pages

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.